Compare Regeneron Pharmaceuticals Inc (REGN) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Synchrony Financial — how do they compare? Regeneron Pharmaceuticals Inc trades at $744.36 (market cap $76.14B), while Synchrony Financial trades at $72.91 (market cap $23.99B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.2× Synchrony Financial's market cap, and Synchrony Financial pays the higher dividend (1.84%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Synchrony Financial for 29 Days on average.
| REGN | SYF | |
|---|---|---|
Market Cap | $76.14B | $23.99B |
Volume | 500,239 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $852.03 | $88.47 |
52-Week Low | $557.73 | $63.78 |
Typical Hold Time | 107 Days | 29 Days |
Enterprise Value | $70.85B | $24.23B |
Dividend Yield | 0.51% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Synchrony Financial (SYF) trades at $72.87, up 1.31% with bullish technical signals despite mixed momentum indicators. The stock shows strong fundamentals with a low P/E of 7.56, robust ROE of 22.23%, and consistent earnings beats. Recent partnerships with OpenAI and Vetspire highlight strategic growth initiatives in AI-driven commerce and veterinary financing.
SYF presents compelling value with attractive valuation metrics and strong profitability, though investors face risks from consumer credit quality and competitive pressures. Analyst consensus targets $87.58 (20% upside) with 61% buy ratings, supporting a positive outlook if the company maintains its earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
